二十碳五烯酸与阿司匹林单用及联用预防结直肠腺瘤:seAFOod息肉预防试验
在英國53个肠癌筛查中心开展的多中心随机双盲安慰剂对照2×2析因试验,纳入709例高危结直肠腺瘤患者,随机接受每日2g EPA游离脂肪酸、300mg阿司匹林、两者联用或安慰剂12个月。1年监测结肠镜腺瘤检出率四组间无显著差异,EPA与阿司匹林单用或联用均未降低腺瘤检出风险,安全性总体可耐受。
要点
- 每日2g EPA或300mg阿司匹林单用及联用12个月,未降低1年腺瘤检出率。
- 四组腺瘤检出率分别为61%、63%、61%和61%,风险比均接近1。
- EPA组胃肠道不良事件数增加,但总体耐受性尚可。
核心结论
- EPA和阿司匹林单用或联用均未减少至少一个结直肠腺瘤的患者比例。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照2×2析因试验,从英国53个肠癌筛查内镜中心招募709例55-73岁高危腺瘤患者。
- 患者按1:1:1:1随机分配至每日2g EPA游离脂肪酸、300mg阿司匹林、联用或安慰剂组,治疗12个月。
- 主要终点为1年监测结肠镜的腺瘤检出率,采用at-the-margins方法分析。
主要发现
- 腺瘤检出率:安慰剂组61%(100/163)、EPA组63%(97/153)、阿司匹林组61%(100/163)、联用组61%(98/161)。
- 至少1例不良事件比例:安慰剂组44%(78/176)、EPA组46%(82/176)、阿司匹林组39%(68/176)、联用组45%(76/176)。
- EPA单用组胃肠道不良事件146例,高于安慰剂组85例、阿司匹林组86例、联用组68例。
关键数值与推荐
- 高危定义:肠癌筛查项目中≥3个腺瘤且至少1个直径≥10mm,或≥5个腺瘤且均<10mm。
- 主要终点腺瘤检出率定义为1年监测结肠镜时至少发现一个腺瘤的参与者比例。
临床怎么用
- 不推荐使用EPA或阿司匹林作为结直肠腺瘤化学预防的常规手段。
- EPA和阿司匹林的最佳使用可能需要基于腺瘤复发特征的精准医学策略。
局限性
- 腺瘤结局数据在EPA组仅有85%可获取,其余组91%-93%,存在失访偏倚可能。
- 研究仅评估1年腺瘤检出率,未报告腺瘤数目、类型和部位等详细结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) and aspirin both have proof of concept for colorectal cancer chemoprevention, aligned with an excellent safety profile. Therefore, we aimed to test the efficacy of EPA and aspirin, alone and in combination and compared with a placebo, in individuals with sporadic colorectal neoplasia detected at colonoscopy. METHODS: In a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial, patients aged 55-73 years who were identified during colonoscopy as being at high risk in the English Bowel Cancer Screening Programme (BCSP; ≥3 adenomas if at least one was ≥10 mm in diameter or ≥5 adenomas if these were <10 mm in diameter) were recruited from 53 BCSP endoscopy units in England, UK. Patients were randomly allocated (1:1:1:1) using a secure web-based server to receive 2 g EPA-free fatty acid (FFA) per day (either as the FFA or triglyceride), 300 mg aspirin per day, both treatments in combination, or placebo for 12 months using random permuted blocks of randomly varying size, and stratified by BCSP site. Research staff and participants were masked to group assignment. The primary endpoint was the adenoma detection rate (ADR; the proportion of participants with any adenoma) at 1 year surveillance colonoscopy analysed in all participants with observable follow-up data using a so-called at-the-margins approach, adjusted for BCSP site and repeat endoscopy at baseline. The safety population included all participants who received at least one dose of study drug. The trial is registered with the International Standard Randomised Controlled Trials Number registry, number ISRCTN05926847. FINDINGS: Between Nov 11, 2011, and June 10, 2016, 709 participants were randomly assigned to four treatment groups (176 to placebo, 179 to EPA, 177 to aspirin, and 177 to EPA plus aspirin). Adenoma outcome data were available for 163 (93%) patients in the placebo group, 153 (85%) in the EPA group, 163 (92%) in the aspirin group, and 161 (91%) in the EPA plus aspirin group. The ADR was 61% (100 of 163) in the placebo group, 63% (97 of 153) in the EPA group, 61% (100 of 163) in the aspirin group, and 61% (98 of 161) in the EPA plus aspirin group, with no evidence of any effect for EPA (risk ratio [RR] 0·98, 95% CI 0·87 to 1·12; risk difference -0·9%, -8·8 to 6·9; p=0·81) or aspirin (RR 0·99 (0·87 to 1·12; risk difference -0·6%, -8·5 to 7·2; p=0·88). EPA and aspirin were well tolerated (78 [44%] of 176 had ≥1 adverse event in the placebo group compared with 82 [46%] in the EPA group, 68 [39%] in the aspirin group, and 76 [45%] in the EPA plus aspirin group), although the number of gastrointestinal adverse events was increased in the EPA alone group at 146 events (compared with 85 in the placebo group, 86 in the aspirin group, and 68 in the aspirin plus placebo group). Six upper-gastrointestinal bleeding events were reported across the treatment groups (two in the EPA group, three in the aspirin group, and one in the placebo group). INTERPRETATION: Neither EPA nor aspirin treatment were associated with a reduction in the proportion of patients with at least one colorectal adenoma. Further research is needed regarding the effect on colorectal adenoma number according to adenoma type and location. Optimal use of EPA and aspirin might need a precision medicine approach to adenoma recurrence. FUNDING: Efficacy and Mechanism Evaluation Programme, a UK Medical Research Council and National Institute for Health Research partnership.
引用
- Hull MA, Sprange K, Hepburn T, et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. Lancet. 2018. PMID: 30466866. doi:10.1016/S0140-6736(18)31775-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。